Improvement of biodistribution and therapeutic index via increase of polyethylene glycol on drug-carrying liposomes in an HT-29/luc xenografted mouse model

TH Chow, YY Lin, JJ Hwang, HE Wang… - Anticancer …, 2009 - ar.iiarjournals.org
Liposomes modified with a high concentration of polyethylene glycol (PEG) could
significantly prolong the retention time of the carried drug in the circulation, thus improving …

Pharmacokinetics and Dosimetry of 111In/188Re-Labeled PEGylated Liposomal Drugs in Two Colon Carcinoma-Bearing Mouse Models

YY Lin, CH Chang, JJ Li, MG Stabin… - Cancer Biotherapy & …, 2011 - liebertpub.com
PEGylated liposomes are important drug carriers for nanomedicine cancer therapy.
PEGylated liposomes can encapsulate radio-and chemo-drugs and passively target tumor …

Evaluation of Pharmacokinetics of 111In-Labeled VNB-PEGylated Liposomes After Intraperitoneal and Intravenous Administration in a Tumor/Ascites Mouse Model

YY Lin, JJ Li, CH Chang, YC Lu, JJ Hwang… - Cancer Biotherapy …, 2009 - liebertpub.com
Nanoliposomes are important drug carriers that can passively target tumor sites by the
enhanced permeability and retention (EPR) effect in neoplasm lesions. This study evaluated …

Influence of PEG coating on the biodistribution and tumor accumulation of pH-sensitive liposomes

SS Nunes, RS Fernandes, CH Cavalcante… - Drug delivery and …, 2019 - Springer
Liposomes are lipid vesicles widely used as nanocarriers in targeted drug delivery systems
for therapeutic and/or diagnostic purposes. A strategy to prolong the blood circulation time of …

Biodistribution and pharmacokinetics of 111In-DTPA-labelled pegylated liposomes in a human tumour xenograft model: implications for novel targeting strategies

KJ Harrington, G Rowlinson-Busza, KN Syrigos… - British journal of …, 2000 - nature.com
The biodistribution and pharmacokinetics of 111 In-DTPA-labelled pegylated liposomes in
tumour-bearing nude mice was studied to examine possible applications of pegylated …

[HTML][HTML] Co-encapsulation of chlorin e6 and chemotherapeutic drugs in a pegylated liposome enhance the efficacy of tumor treatment: Pharmacokinetics and …

PC Peng, RL Hong, T Tsai, CT Chen - Pharmaceutics, 2019 - mdpi.com
Long-circulating PEG-modified liposome has been shown to improve pharmacokinetic
properties and reduce systemic toxicity in cancer treatment. However, drug bioavailability …

[HTML][HTML] PEGylated versus non-PEGylated pH-sensitive liposomes: new insights from a comparative antitumor activity study

SS Nunes, J de Oliveira Silva, RS Fernandes… - Pharmaceutics, 2022 - mdpi.com
PEGylated liposomes are largely studied as long-circulating drug delivery systems.
Nevertheless, the addition of PEG can result in reduced interactions between liposomes and …

Intra-tumor distribution of PEGylated liposome upon repeated injection: No possession by prior dose

H Nakamura, ASA Lila, M Nishio, M Tanaka… - Journal of Controlled …, 2015 - Elsevier
Liposomes have proven to be a viable means for the delivery of chemotherapeutic agents to
solid tumors. However, significant variability has been detected in their intra-tumor …

Effect of doxorubicin release rate from polyethylene glycol-modified liposome on anti-tumor activity in B16-BL6 tumor-bearing mice

M Maruyama, H Tojo, K Toi, Y Ienaka, K Hyodo… - Journal of …, 2022 - Elsevier
To investigate the effect of doxorubicin (DOX) release rates from polyethylene glycol (PEG)-
liposomes on the anti-tumor activity, several in-vitro and in-vivo studies were performed by …

Enhanced retention and anti-tumor efficacy of liposomes by changing their cellular uptake and pharmacokinetics behavior

Y Li, R Liu, J Yang, Y Shi, G Ma, Z Zhang, X Zhang - Biomaterials, 2015 - Elsevier
Although PEGylated liposome-based drug delivery systems hold great promising
applications for cancer therapy due to their prolonged blood circulation time, PEGylation …